Spinal Fusion (INFUSE Bone Graft)

The pivotal clinical trial by Burkus et al. (2002) demonstrated that INFUSE (rhBMP-2/ACS in a threaded titanium cage) achieved fusion rates of 94-100% in anterior lumbar interbody fusion, comparable to autologous iliac crest bone graft while eliminating harvest-site morbidity. FDA approval followed for single-level ALIF in 2002.

However, off-label use expanded rapidly to posterior and anteroposterior cervical spine procedures, where serious complications emerged including life-threatening cervical swelling, airway compromise, and dysphagia. A 2011 investigation by Carragee et al. in The Spine Journal challenged the safety data from industry-sponsored trials, reporting complication rates 10-50 times higher than originally published.

Tibial Fracture Repair

The BESTT trial by Govender et al. (2002) showed that rhBMP-2 applied during initial surgical fixation of open tibial fractures significantly reduced the need for secondary interventions and accelerated fracture healing. The 1.5 mg/mL dose group showed a 44% reduction in secondary procedures compared to standard care.

Heterotopic Ossification

The formation of bone at unintended anatomical sites remains BMP-2's most problematic adverse effect. Dmitriev et al. (2012) documented heterotopic ossification rates as high as 70% in some clinical series, with bone forming in paravertebral muscles, nerve foramina, and the spinal canal. This complication appears dose-dependent and may be driven by the supraphysiological concentrations required for clinical effect.

Cancer Risk Controversy

The potential association between rhBMP-2 and cancer risk has been intensely debated. Carragee et al. (2013) reported a higher cancer incidence in BMP-2-treated patients versus controls in a retrospective analysis. Subsequent larger studies including a Medicare database analysis found no significant association. The question remains unresolved, with biological plausibility existing through BMP-2's effects on angiogenesis and cell proliferation.

Peptide Mimetics

Given the complications associated with supraphysiological rhBMP-2 doses, synthetic peptide mimetics have emerged as promising alternatives. The P24 peptide, derived from the knuckle epitope of BMP-2, promotes osteogenesis when delivered on various scaffolds. Lin et al. (2017) demonstrated that P24-loaded PLGA scaffolds achieve significant bone regeneration in critical-size defects. The P28 peptide shows similar promise with enhanced stability. These mimetics offer advantages in manufacturing cost, shelf stability, and reduced inflammatory response compared to the full recombinant protein.

Spinal fusion

Recombinant human BMP-2 (INFUSE) was the first osteoinductive growth factor approved to replace autologous bone graft in anterior lumbar interbody fusion. It reliably induces new bone and eliminates iliac-crest donor-site morbidity, but a landmark 2013 individual-patient-data meta-analysis (Yale University Open Data Access project) concluded it offers little clinical advantage over autograft in overall fusion success while carrying distinct early risks, and highlighted underreporting in earlier industry-sponsored publications.

• Non-inferior to superior fusion rates versus autograft in on-label single-level ALIF
• Eliminates iliac-crest graft harvest and its associated chronic donor-site pain
• Off-label posterolateral/cervical use is associated with ectopic bone, radiculitis, seroma and airway swelling

Fracture healing and orthopedic trauma

In open tibial fractures, rhBMP-2 delivered on a collagen sponge accelerated bony union and reduced repeat operations in the pivotal BESTT trial, establishing it as an adjunct in severe open fractures. Its role is dose- and carrier-dependent, and enthusiasm has been tempered by cost and by concerns about supraphysiologic dosing.

• 1.5 mg/mL rhBMP-2 reduced secondary interventions by ~44% in open tibial fractures
• Fewer infections and hardware failures in the treated group
• Optimal effect requires an appropriate osteoconductive/compression-resistant carrier

Safety, dosing and oncogenicity signals

Because rhBMP-2 is a potent osteoinductive morphogen used at doses far above physiologic levels, research has focused on adverse effects: ectopic bone formation, postoperative inflammation, retrograde ejaculation with anterior approaches, and a debated association with new cancers at high spinal doses. Current consensus supports on-label use at established doses while discouraging high-dose off-label application.

• Dose-dependent local inflammation and heterotopic ossification
• FDA public-health notification against off-label cervical use
• Cancer-risk signal at high doses seen in some but not all long-term analyses, keeping dosing conservative